Provided by Tiger Fintech (Singapore) Pte. Ltd.

Summit Therapeutics PLC

29.32
+2.258.31%
Pre-market: 29.390.0700+0.24%07:33 EDT
Volume:2.91M
Turnover:83.64M
Market Cap:21.77B
PE:-86.35
High:29.56
Open:27.40
Low:26.90
Close:27.07
Loading ...

Summit Therapeutics Announces Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4)

Reuters
·
17 May

Stock Track | Summit Therapeutics Soars 5.15% as TD Cowen Initiates Coverage with Buy Rating

Stock Track
·
09 May

Stock Track | Summit Therapeutics Soars 5.15% as TD Cowen Initiates Coverage with Buy Rating

Stock Track
·
09 May

TD Cowen Initiates Summit Therapeutics at Buy

MT Newswires Live
·
08 May

U.K. New-Car Sales Fell in April as New Taxes Hit, Industry Body SMMT Says

Dow Jones
·
06 May

Summit Therapeutics (SMMT) Receives a Buy from Truist Financial

TIPRANKS
·
05 May

Why Summit Therapeutics Inc. (SMMT) Soared Last Week

Insider Monkey
·
04 May

Stock Track | Summit Therapeutics Soars 6.61% Despite Q1 Earnings Miss, Buoyed by Analyst Optimism

Stock Track
·
02 May

Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil

Zacks
·
02 May

Summit Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
02 May

Summit Therapeutics Q1 Loss Widens; Cash Equivalents Drop

MT Newswires Live
·
02 May

Earnings Flash (SMMT) Summit Therapeutics Q1 Adjusted Loss $0.07 vs. $0.05 Loss Year Ago

MT Newswires Live
·
02 May

Summit Therapeutics Q1 Adj. EPS $(0.07) Beats $(0.09) Estimate

Benzinga
·
02 May

BRIEF-Summit Therapeutics Q1 Net Income USD -62.9 Million

Reuters
·
02 May

Summit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past Month

Simply Wall St.
·
01 May

Summit Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
30 Apr

Summit Therapeutics Price Target Maintained With a $40.00/Share by JMP Securities

Dow Jones
·
28 Apr

Akeso survival data for ivonescimab misses expectations, STAT says

TipRanks
·
27 Apr

BUZZ-Summit Therapeutics closes 36% lower after interim data for cancer drug

Reuters
·
26 Apr

Summit Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
26 Apr